Anti-PD1 Antibodies + IDO Inhibitor and Other Treatments in Melanoma May Be in Clinical Practice within One Year

Anti-PD1 Antibodies + IDO Inhibitor and Other Treatments in Melanoma May Be in Clinical Practice within One Year

User Photo
AnnualMeeting-SITC2017

3 years
491 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Lawrence Fong, MD of University of California, San Francisco discusses upcoming combination therapies for melanoma treatment that will be FDA approved and used in clinical practice at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
Up Next Autoplay
>